HOME>Our Products>Marketed & Pipeline Products for the treatments of central nervous system (CNS) disorders
Innovation today, healthier tomorrows

Marketed & Pipeline Products for the

treatments of central nervous system

(CNS) disorders

Our recognition of an unmet patient need is what originally led Sunovion to conduct research and clinical programs in the broad category of CNS disorders.

For people struggling with other CNS disorders, Sunovion is actively working on treatments in still earlier stages of development. The strength of our drug discovery program reflects our long-term commitment to helping people live better in the future with difficult conditions such as anxiety disorders, pain management, and depression. We're optimistic that our discovery efforts in these areas will one day provide patients with safe and effective treatments leading to positive outcomes.


Epilepsy is one of the most common neurological disorders and, according to the Centers for Disease Control and Prevention, affects nearly 2.2 million people in the United States.

Nearly one-third of people living with epilepsy are unable to control their seizures; therefore, there continues to be a need for new therapies.

Partial-onset seizures are the most prevalent seizure type, accounting for 60% of new epilepsy diagnoses.

On November 8, 2013, the U.S. Food and Drug Administration (FDA) approved Aptiom® (eslicarbazepine acetate) tablets, an antiepileptic drug (AED), for use as adjunctive treatment of partial-onset seizures.


Schizophrenia is a chronic, disabling and serious brain disorder that affects approximately 2.4 million American adults or 1 in 100 people. The World Health Organization ranks schizophrenia as the sixth leading cause of disability worldwide. Schizophrenia typically starts in the late teens to mid-30s and equally affects men and women and all ethnic and racial groups Schizophrenia is a chronic, disabling, and serious medical illness. Its causes are not well understood. People with schizophrenia can suffer from a wide range of symptoms, including hallucinations, delusions, disorganized thinking, lack of emotion, and the inability to make decisions, among others.

On October 28, 2010, the U.S. FDA approved Sunovion's Latuda® (lurasidone HCl) tablets for adult patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States and Puerto Rico. Please see Medication Guide and Boxed Warnings at www.LATUDA.com.

Bipolar Depression

On June 28, 2013, the U.S. FDA approved Sunovion's LATUDA for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunctive therapy with lithium or valproate. Please see Medication Guide and Boxed Warnings at www.LATUDA.com.


The success of Lunesta® (eszopiclone), a widely prescribed sleep aid, was the motivation for Sunovion's expanding research and development in this treatment area.

Related Links

> Aptiom® (eslicarbazepine acetate)

> Latuda® (lurasidone HCl) - Schizophrenia

> Latuda® (lurasidone HCl) - Bipolar Depression

> Lunesta® (eszopiclone)

> Drug discovery